Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCENT 3 long-term extension of mirikizumab in ulcerative colitis
2023-507657-15-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Primary endpoint: Clinical remission. Planned start Sep 2018; status: authorised.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-507657-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507657-15-00.